Prevention & lipidsResearch article
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population
- Cost-effectiveness analysis (discrete-event simulation model)
- health care sector perspective
- 10-year time horizon
- 1-way and probabilistic sensitivity analysis
Authors' conclusion
Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services.
Study context
- Population
- Southern Community Cohort Study (SCCS) Polypill Trial-representative cohort (majority Black, low-income population) and trial-eligible non-Hispanic Black US adultssimulated trial-representative cohort
- Participants
- 100,000 participants
- Comparison
- Polypill vs usual care
- Outcome
- Direct health care costs (US dollar 2023) and QALYs, both discounted 3% annually, and incremental cost per QALY gained
- Follow-up
- 10 years
Main finding
As reported in the abstract
Incremental QALYs and cost per QALY gained
- at a cost of approximately $10 152 000
- additional quality-adjusted life-years (QALYs) (mean) 1190 QALYs (95% uncertainty interval UI 287–2159)
- Incremental QALYs and cost per QALY gained
- incremental cost per QALY gained $8560 per QALY gained
- High value (<$50 000 per QALY gained) in proportion of simulations
- 99%
- High value when priced at or below, per year
- $559
- Cost saving when priced at or below, per year
- $443
Further findings
| Outcome | incremental cost per QALY gained (per QALY gained) |
|---|---|
| Cost per QALY gained, trial-eligible non-Hispanic Black US adults (secondary analysis) · n = 3 602 427; high value | $13 400 |
Original publication
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population. JAMA Cardiol. Published 1 March 2025. doi:10.1001/jamacardio.2024.4812
Summarised from the published abstract; every number is checked against it